Stifel Virtual Immunology and Inflammation Forum September 16, 2025 12:30 PM EDTCompany ParticipantsMartin Babler - President, ...
Drs Anne Cross and Scott Newsome discuss new horizons in MS treatment strategies, including the TREAT-MS trial and shared decision-making for optimal patient care.
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New ...
At Year 2, reductions were observed in key biomarkers, including serum glial fibrillary acidic protein (GFAP), immunoglobulin G (IgG) index, and C-X-C motif chemokine ligand 13 (CXCL-13) levels.
The 2025 Congress of Clinical Rheumatology West will feature expanded immunology and young investigator programs, as well as ...
A self-administered, under-the-skin injection version of Saphnelo is effective for reducing disease severity in adults with ...
Dr Jiwon Oh looks forward to hearing updates on major clinical trials and long-term studies of new and emerging MS treatments at ECTRIMS 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback